ISHL12 2022 | The importance of PD1 blockade in the treatment of classical HL
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the growing role of PD1 blockade in the treatment of classical Hodgkin lymphoma (cHL), commenting on the importance of trying to integrate PD1 inhibitors in the frontline setting. Dr Collins also highlights how PD1 inhibitors can be integrated in treatment algorithms to reduce chemotherapy-related toxicities. This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Received honoraria for speaker and advisory work from:
Takeda, Gilead, Roche, Novartis, Incyte, Daiichi Sankyo, Beigene, ADC Therapeutics, Celleron, SecuraBio
Received research funding from:
BMS, MSD, Pfizer, Amgen, Celgene, Beigene
